FDA Raids Maker of ‘Poppers’ Inhalant Drug, Company Says

The FDA said that it will not make comments on ‘possible criminal investigations.’

Signage outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, on Aug. 29, 2020. Andrew Kelly/Reuters

The U.S. Food and Drug Administration (FDA) has cracked down on at least one manufacturer of a type of inhalant drug known as “poppers,” according to a recent statement by that manufacturer.

Double Scorpio, a Texas-based manufacturer of the inhalant, said in a statement on its website last week that it has “stopped all operations following a search and seizure” at its offices by the FDA.